Tag
Healthcare Diagnostics
6 articles
Healthcare diagnostics companies present a mixed picture, with some demonstrating strong growth while others face challenges. Molbio Diagnostics reported a significant turnaround in Q1 FY27, achieving profitability and substantially increasing test kit sales, driven by operating leverage and domestic demand. Conversely, Aspira Pathlab experienced a considerable decline in profit for FY26 and is undergoing leadership changes, while TCM Limited reported a substantial consolidated loss. These varied results highlight the diverse competitive landscape and operational hurdles within the sector, suggesting investors should carefully evaluate individual company fundamentals and growth trajectories amid evolving market dynamics.
Metropolis Healthcare Q2 Revenue Up 15% YoY
Metropolis Healthcare reports 15% YoY revenue growth for Q2 FY27 driven by patient volume and test realizations.
TruHealth Wellness and Specialty segments were the fastest-growing segments during the
Suraksha Diagnostic 21st AGM Voting Results
Suraksha Diagnostic held its 21st AGM via video conference on September 22, 2026, to vote on five ordinary resolutions.
All five resolutions were passed, including adoption of FY26 financial statement
Molbio Diagnostics Q1 FY27 Revenue ₹408 Crore
Molbio reported Q1 FY27 consolidated revenue of ₹408 crore with an EBITDA margin of 25% and PAT of ₹52.7 crore.
Management provided FY27 growth guidance of ~25% revenue growth and 24-25% EBITDA margin
Molbio Diagnostics Q1 PAT at ₹52.74 Cr
Molbio Diagnostics reported Q1 FY27 unaudited results with Total Income of ₹411.48 Cr, a significant increase from ₹100.47 Cr in Q1 FY26.
EBITDA improved to ₹103.68 Cr profit from a ₹14.50 Cr loss in
Thyrocare Promoter Docon Sells 9.9% Stake
Promoter Docon Technologies sold 1.58 crore Thyrocare shares representing 9.9% equity via market trades on August 13, 2026.
Post-sale, promoter shareholding reduced from 60.92% to 51.02% of total paid
Thyrocare Promoter Releases Pledge on 17.5M Shares
Docon Technologies, Thyrocare's promoter, released pledge on 1.75 crore equity shares (10.99% stake) held as security for API Holdings' NCDs.
The pledge release on August 11, 2026, reduces Docon's enc